The city-based Orchid Chemicals and Pharmaceuticals Ltd today announced a 50:50 joint venture with the $680 million North China Pharmaceutical Corporation (NCPC), the largest pharmaceutical group in China.
The venture, called NCPC Orchid Pharmaceuticals Co Ltd, will manufacture and market injectible antibiotics in China. It will be based in Shijiazhuang in north China and is expected to start production by January 2003.
Orchid Pharma managing director Raghavendra Rao said the joint venture was with a subsidiary of China
